Real wOrld studY in the Adjuvant Setting for High Risk earLy Breast Cancer Patients

Sponsor
Azienda Ospedaliero-Universitaria di Modena
Study ID
NCT07151911
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The primary goal of this observational study is to describe the distribution of treatment options and patients' characteristics according to the definition of high-risk status in the early breast cancer (EBC) setting. Participants already taking intervention as part of their regular medical care for EBC will answer questionnaires to also assess quality of life and patient reported outcomes. The recruitment phase will last about 2 years, each patient will be followed up for 5 years.

Key Dates

Start date
Aug 26, 2024
Status verified
Aug 2025
Primary completion
Sep 30, 2026
Completion
Sep 30, 2031

Study Design

Enrollment
100 participants (estimated)

Arms

  • Arm: ADJUVANT IN EBC
    High-risk HR positive, Her2 negative early breast cancer patients receiving abemaciclib, olaparib and endocrine therapy.

Primary Outcome Measure

Distribution of treatment options [ Time Frame: From enrollment to the end of treatment at 5 years ]

Central Contacts

Related Studies